Alembic Pharma Gets USFDA Approval for Diltiazem ER Capsules

21 Oct 2024 , 12:26 PM

Alembic Pharmaceuticals Limited received final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP. The approved strengths include 120 mg, 180 mg, and 240 mg. Diltiazem Hydrochloride is prescribed to treat hypertension (high blood pressure) and chronic stable angina (chest pain).

The drug can be used alone or combined with other antihypertensive drugs like diuretics. These capsules are therapeutically equivalent to Allergan’s Dilacor XR Extended-Release Capsules.

At the time of writing on October 21, 2024 at 12:24 pm, shares of Alembic Pharmaceuticals is trading at ₹1156.95 which is a 0.28% dip than the previous close. Alembic Pharmaceuticals has gained 53% in the last one year, and 51% since the beginning of the year.

The US market size for Diltiazem Hydrochloride Extended-Release Capsules is valued at $28.2 million for the twelve months ending June 2024.

The approval strengthens Alembic’s presence in the US market, further expanding its portfolio. This approval brings Alembic’s total ANDA approvals to 217, of which 190 are final approvals.

Alembic Pharmaceuticals continues to grow its footprint in the US, with this approval contributing to its robust portfolio of generic medications.